{"id":3908,"date":"2025-09-01T23:53:32","date_gmt":"2025-09-01T23:53:32","guid":{"rendered":"https:\/\/modafinil.pl\/?post_type=product&p=3908"},"modified":"2026-10-03T05:51:54","modified_gmt":"2026-10-03T05:51:54","slug":"chlodantane","status":"publish","type":"product","link":"https:\/\/modafinil.pl\/en\/sklep\/chlodantane\/","title":{"rendered":"Chlodantane (CAS 185384-80-9) \u2014 Chemical Reagent 1000 mg, Purity \u2248 95.3%"},"content":{"rendered":"

N-(2-adamantyl)-4-chlorobenzamide<\/strong> (Chlodantane), crystalline powder, 1000 mg package. Material intended exclusively for laboratory and analytical in vitro research<\/strong>. This product is not intended for consumption by humans or animals<\/strong>, it is not a medicinal product, a dietary supplement, a food product, or a cosmetic.<\/p>\n

The thing that needs to be said up front<\/h2>\n

Chlodantan is a chemical compound with a fully defined structure, but without any dedicated scientific literature<\/strong>. A search of the PubMed database for the name “Chlodantane”, CAS number 185384-80-9, and the systematic name returns no work devoted to this compound. The only match for the phrase “Chlodantane” is a review paper on adamantane derivatives in general (Morozov et al., 1999) \u2014 found through a partial word match, not through an actual description of this molecule, and already used in the literature of a competing shop, so we exclude it for that reason as well.<\/p>\n

Registry data says more than the silence of the literature. The structure has been listed in PubChem as CID 959689 since July 9, 2005, indexed by chemical supplier databases and screening libraries (ChemDB, ABI Chem, BLD Pharm, ZINC), in the EPA DSSTox registry, and in PATENTSCOPE (WIPO) \u2014 without a patent assigned directly to the compound. In ChEMBL (CHEMBL4111629) it has the status “Preclinical”<\/strong> (clinical development phase: 0) and no assigned mechanism of action. In other words: the compound is catalogued chemically<\/strong>, but has never entered any documented research program into biological activity.<\/p>\n

This puts Chlodantan in a different situation than bromantan<\/a>, whose history \u2014 a Soviet actoprotector program, three research centers, more than a dozen preclinical studies, and clinical trials conducted using a medicinal product registered in Russia (trade name described on the bromantan page) \u2014 is documented with dates. Calling Chlodantan an “analog of bromantan” is justified structurally (both are substituted 2-aminoadamantanes), but does not transfer a single research result onto it<\/strong>. For completeness, we also checked what a query for the related chemical class “adamantyl benzamide” actually returns \u2014 real papers exist, but they concern an entirely different pharmacology; we list them below in the References section, clearly marked as not pertaining to this compound.<\/p>\n

Three different entities that must not be confused<\/h2>\n\n\n\n\n\n\n\n
Separating the layers: substance \u2014 medicinal product \u2014 reagent<\/caption>\n
Entity<\/th>\nWhat it is<\/th>\nStatus of Chlodantan<\/th>\n<\/tr>\n<\/thead>\n
Chemical substance
Chlodantan, CAS 185384-80-9<\/th>\n		A chemical concept \u2014 a molecule with a defined structure, registered in chemical databases (PubChem, ChEMBL).<\/td>\nyes<\/strong> \u2014 this is the only status this molecule actually has<\/td>\n<\/tr>\n
Medicinal product<\/th>\nA pharmaceutical preparation: pharmaceutical form, GMP regime, registration documentation, safety oversight.<\/td>\nNO \u2014 in any country.<\/strong> The compound has never even entered Phase I clinical trials (ChEMBL: phase 0)<\/td>\n<\/tr>\n
Chemical reagent
material offered here<\/th>\n		Material for laboratory and analytical work. It does not have, and cannot have, approval for use in humans or animals.<\/strong><\/td>\nyes<\/strong> \u2014 and it is offered exclusively in this capacity<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

The consequence is unambiguous.<\/strong> There is no registered medicinal product containing this substance, so there is no risk of confusing the reagent with a drug \u2014 but there are also no clinical or preclinical studies to refer to. The only data we have concern the molecule’s structure and its physicochemical behavior<\/strong>, and a rigorous description of this material is limited to that. The reagent is not a form in which anything was ever studied \u2014 because this molecule was not studied at all.<\/p>\n

Reagent identification card<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Registry data and identifiers \u2014 Chlodantan<\/caption>\n
Systematic name (IUPAC)<\/th>\nN-(2-adamantyl)-4-chlorobenzamide<\/td>\n<\/tr>\n
Common name<\/th>\nChlodantan (Chlodantane)<\/td>\n<\/tr>\n
CAS number<\/th>\n185384-80-9<\/td>\n<\/tr>\n
Molecular formula<\/th>\nC17<\/sub>H20<\/sub>ClNO<\/td>\n<\/tr>\n
Molar mass<\/th>\n289.80 g\u00b7mol\u22121<\/sup><\/td>\n<\/tr>\n
Monoisotopic mass<\/th>\n289.1233 Da<\/td>\n<\/tr>\n
InChIKey<\/th>\nVOHIYJJUKAUCCU-UHFFFAOYSA-N<\/td>\n<\/tr>\n
SMILES<\/th>\nC1C2CC3CC1CC(C2)C3NC(=O)C4=CC=C(C=C4)Cl<\/td>\n<\/tr>\n
PubChem CID<\/th>\n959689<\/a><\/td>\n<\/tr>\n
ChEMBL<\/th>\nCHEMBL4111629 \u2014 status “Preclinical” (phase 0)<\/td>\n<\/tr>\n
Form<\/th>\ncrystalline powder, white to off-white<\/td>\n<\/tr>\n
Purity<\/th>\n\u2248 95.3%<\/td>\n<\/tr>\n
Intended use<\/th>\nresearch reagent \u2014 not for consumption by humans or animals<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Lineage of the molecule: the adamantane cage and Chlodantan’s place in this family<\/h2>\n

The core of the molecule is the same adamantane<\/strong> that underlies bromantan<\/a> \u2014 a cage hydrocarbon isolated from petroleum in the 1930s, available on a preparative scale only after the development, in the late 1950s, of a synthesis using a Lewis acid-catalyzed rearrangement. Substitution of the cage with an amino group at position 2 gave the 2-aminoadamantane<\/strong> family, to which \u2014 at least in terms of the carbon skeleton \u2014 Chlodantan also belongs.<\/p>\n

Amide, not amine: where Chlodantan departs from bromantan<\/h3>\n

Here, however, the structural similarity ends. Bromantan is a secondary aromatic amine<\/strong> \u2014 the nitrogen atom connects the adamantane cage directly to the 4-bromophenyl ring (Ar\u2013NH\u2013adamantyl). Chlodantan is a benzoic acid amide<\/strong> \u2014 a carbonyl group is inserted between the nitrogen and the 4-chlorophenyl ring (Ar\u2013C(=O)\u2013NH\u2013adamantyl). This is not a minor cosmetic difference: amides and secondary aromatic amines have different metabolic stability, a different basicity profile, and a different synthetic route (acylation with an acid chloride instead of reductive amination or coupling). Treating Chlodantan as a simple “chlorine instead of bromine” substitution on the bromantan skeleton is therefore inaccurate \u2014 it is a different functional class on the same core.<\/p>\n

The molecule has appeared in chemical registries since 2005, but \u2014 unlike bromantan \u2014 without an accompanying publication explaining why it was synthesized. The most likely context is combinatorial chemistry practice: coupling available amines (including aminoadamantanes) with available acid chlorides in screening compound libraries, without a dedicated pharmacological program. This is not a claim we can confirm from a source \u2014 we note it as the most likely explanation for the absence of literature, not as a fact.<\/p>\n

Status in databases and registries<\/h2>\n\n\n\n\n\n\n\n\n\n
Facts with dates: what is known about Chlodantan and how we know it<\/caption>\n
July 9, 2005<\/th>\nstructure registered in PubChem as CID 959689<\/td>\n<\/tr>\n
no date<\/th>\npresence in chemical supplier catalogs and screening libraries: ChemDB, ABI Chem, BLD Pharm, ZINC (ID ZINC568772)<\/td>\n<\/tr>\n
no date<\/th>\nregistration in EPA DSSTox (DTXSID201376531) \u2014 a structural inventory, not evidence of toxicological studies<\/td>\n<\/tr>\n
no date<\/th>\npresence in PATENTSCOPE (WIPO) \u2014 appearing in the patent database, without a patent assigned directly to the compound (a PatentID query in PubChem returns no results)<\/td>\n<\/tr>\n
no date<\/th>\nChEMBL CHEMBL4111629: status “Preclinical”, clinical development phase 0, no assigned mechanism of action<\/td>\n<\/tr>\n
July 3, 2026<\/th>\nsynchronization of physicochemical data in our system with PubChem<\/td>\n<\/tr>\n
September 7, 2026<\/th>\nverification of PubMed literature for this description \u2014 0 papers directly concerning this compound<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Chemistry and what it means for the laboratory<\/h2>\n

The carbonyl that changes everything<\/h3>\n

Inserting a carbonyl group between the nitrogen and the aromatic ring has measurable analytical consequences that can be stated without referring to any biological studies:<\/p>\n\n\n\n\n\n\n\n\n\n\n
Descriptor comparison: bromantan and Chlodantan<\/caption>\n
Parameter<\/th>\nBromantan<\/th>\nChlodantan<\/th>\nSignificance<\/th>\n<\/tr>\n<\/thead>\n
Molecular formula<\/th>\nC16<\/sub>H20<\/sub>BrN<\/td>\nC17<\/sub>H20<\/sub>ClNO<\/td>\nadditional C and O atom (carbonyl), Br replaced by Cl<\/td>\n<\/tr>\n
Molar mass<\/th>\n306.24<\/td>\n289.80<\/strong><\/td>\nlower by about 16.4 despite the additional carbonyl \u2014 chlorine is much lighter than bromine<\/td>\n<\/tr>\n
XLogP (computed)<\/th>\n\u2248 5<\/td>\n\u2248 4.2<\/strong><\/td>\nslightly lower lipophilicity \u2014 earlier elution in RP-HPLC than bromantan<\/td>\n<\/tr>\n
Polar surface area (PSA)<\/th>\n12 \u00c52<\/sup><\/td>\n29.1 \u00c52<\/sup><\/strong><\/td>\nmore than twice as high \u2014 the effect of the carbonyl oxygen, absent in bromantan<\/td>\n<\/tr>\n
Hydrogen bond donors \/ acceptors<\/th>\n1 \/ 1<\/td>\n1 \/ 1<\/td>\nthe count is unchanged, but the character differs: in Chlodantan the acceptor is the carbonyl oxygen, not the nitrogen lone pair<\/td>\n<\/tr>\n
Rotatable bonds<\/th>\n2<\/td>\n2<\/td>\nunchanged<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Chlorine versus bromine: isotopic signature in mass spectrometry<\/h3>\n

Just as with bromantan, the halogen atom gives a recognizable signature in the mass spectrum \u2014 but an inverted one. Bromine has two stable isotopes in a ratio close to 1:1<\/strong> (79<\/sup>Br and 81<\/sup>Br), giving a pair of peaks of nearly equal height. Chlorine also has two stable isotopes, 35<\/sup>Cl and 37<\/sup>Cl, but in a natural ratio close to 3:1<\/strong> \u2014 a parent ion peak and a peak two mass units higher, with the latter at about one-third the height of the former. For the laboratory, this means that the shape of the isotope cluster alone allows a chlorine compound to be distinguished from a bromine compound even before the exact mass is read \u2014 and the 16.4 Da mass difference between Chlodantan and bromantan makes the distinction even simpler.<\/p>\n

Physicochemical characteristics<\/h3>\n\n\n\n\n\n\n\n\n
Computed descriptors of Chlodantan and their analytical significance<\/caption>\n
Parameter<\/th>\nValue<\/th>\nWhat this means<\/th>\n<\/tr>\n<\/thead>\n
Partition coefficient (XLogP)<\/th>\n\u2248 4.2<\/td>\nhigh lipophilicity \u2014 the compound elutes late in reversed-phase chromatography<\/td>\n<\/tr>\n
Topological polar surface area<\/th>\n29.1 \u00c52<\/sup><\/td>\nmoderate \u2014 higher than in bromantan, lower than in multifunctional compounds<\/td>\n<\/tr>\n
Heavy atoms<\/th>\n20<\/td>\nmolecular size comparable to bromantan (18)<\/td>\n<\/tr>\n
Solubility<\/th>\ngood in DMSO; negligible in water<\/td>\nprepare stock solutions in an organic solvent<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Nomenclature and synonyms<\/h2>\n